Challenges and approaches for the development of safer immunomodulatory biologics-Reference-Cited by-同舟云学术

Challenges and approaches for the development of safer immunomodulatory biologics

Published:2013-03-28 Issue:4 Volume:12 Page:306-324
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Sathish Jean G.,Sethu Swaminathan,Bielsky Marie-Christine,de Haan Lolke,French Neil S.,Govindappa Karthik,Green James,Griffiths Christopher E. M.,Holgate Stephen,Jones David,Kimber Ian,Moggs Jonathan,Naisbitt Dean J.,Pirmohamed Munir,Reichmann Gabriele,Sims Jennifer,Subramanyam Meena,Todd Marque D.,Van Der Laan Jan Willem,Weaver Richard J.,Park B. Kevin

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd3974.pdf

Reference182 articles.

1. Swinney, D. C. & Anthony, J. How were new medicines discovered? Nature Rev. Drug Discov. 10, 507–519 (2011).

2. Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics: a summary and pharmacological classification. Nature Rev. Drug Discov. 7, 21–39 (2008).

3. Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A. & George, A. J. The safety and side effects of monoclonal antibodies. Nature Rev. Drug Discov. 9, 325–338 (2010). This is a comprehensive discussion of adverse reactions associated with mAbs, including immunomodulatory mAbs.

4. Sorensen, P. S. et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult. Scler. 18, 143–152 (2012). This article reviews the risk factors for PML in patients receiving natalizumab therapy and discusses the importance of patient stratification based on risk.

5. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alginate/silk fibroin/Zn2+ composite microspheres for site-specific delivery for enhanced ulcerative colitis therapy;Chemical Engineering Journal;2024-09

2. Cancer treatments as paradoxical catalysts of tumor awakening in the lung;Cancer and Metastasis Reviews;2024-07-04

3. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC);Clinical Pharmacology & Therapeutics;2024-06-07

4. Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions;Cancers;2024-05-27

5. Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy;Advances in Cancer Immunotherapy [Working Title];2024-05-15